Taichu Group - Integrated Innovation-Driven Platform for Preclinical Drug Development Services

Taichu Biotechnology

Pre-Clinical Research(CRO)

Taichu Bio, a Shanghai-based contract research organization (CRO) founded in 2020 and headquartered in Life Bay Park, Lingang Special Area, specializes in nonclinical research and development services for innovative therapeutics. Operating under NMPA-GLP certification and full AAALAC International accreditation, the company delivers end-to-end solutions encompassing drug candidate screening, pharmacodynamic (PD) evaluation, pharmacokinetic (PK) studies, and nonclinical safety assessments (including GLP-compliant toxicology, genotoxicity, and safety pharmacology). Its leadership team, composed of globally renowned scientists with over three decades of combined expertise in pharmacology and toxicology, drives robust technical development capabilities and protocol design rigor. Taichu Bio's integrated platform supports clients in streamlining drug development processes through scientifically validated models, regulatory-aligned study execution, and translational insights spanning oncology, immunology, and rare disease pipelines.

Business scope

Team experience

Its leadership team, composed of globally renowned scientists with over three decades of combined expertise in pharmacology and toxicology, drives robust technical development capabilities and protocol design rigor.

20+

The team members bring an average of 20+ years of hands-on experience in PD/PK/Tox.
120 +

Help clients obtain more than 120 IND approvals from FDA,Netherlands, Poland, Australia and other countries.
630 +

Service for around 630 pharmaceutical companies and organizations.
1200+

Complete more than 1200 services in PD/PK/Tox.
8000 +

Complete more than 8000 services.

Project experience

Experience in preclinical pharmacodynamics research

Organoid Research:Successfully established 14 PDO (Patient-Derived Organoid) models, covering major pathological types including HGSC (High-Grade Serous Carcinoma), EMC (Endometrioid Carcinoma), CCC (Clear Cell Carcinoma), SBT (Serous Borderline Tumor), etc.

Skeletal System Pharmacodynamic Studies:Models for osteoporosis, osteoarthritis, rheumatoid arthritis, etc.

Analgesic Drug Screening and Evaluation: Models for inflammatory pain, neuropathic pain, cancer-induced bone pain, incisional pain, etc.

Hair Growth Drug Screening and Evaluation:Models for androgenetic alopecia, alopecia areata, etc.

Oncology Pharmacodynamic Studies:Models for liver cancer, lung cancer, renal cell carcinoma, breast cancer, ovarian cancer, gastric cancer, lymphoma, melanoma, glioma, etc.

Cardiovascular and Cerebrovascular Pharmacodynamic Studies:Models for ischemic stroke, myocardial ischemia, hypertension, arrhythmia, hyperlipidemia/atherosclerosis, etc.

Neurological and Psychiatric Pharmacodynamic Studies:Models for Alzheimer's disease, Parkinson's disease, epilepsy, spinal cord/brain injury, cerebral vasospasm, depression, etc.

SARS-CoV-2 (COVID-19) Neutralizing Antibody Efficacy Testing

RSV (Respiratory Syncytial Virus) Neutralizing Antibody Titer Assay

Pharmacodynamics Research on MSC Therapy for cIschemic Stroke, Ankylosing Spondylitis, and aGVHD, etc.
Experience in pre-clinical toxicology research

Comprehensive Toxicology Research: Evaluating Safety Profiles of Small Molecules, Biologics (Antibodies, ADCs, AOCs, Peptides/Proteins), and Advanced Therapies (Nucleic Acid Drugs, Cell & Gene Therapies).